APA (7th ed.) Citation

Jiang, X., Wu, Q., Opoku, Y. K., Zou, Y., Wang, D., Hu, C., & Ren, G. (2022). Fibroblast growth factor 21 attenuates the progression of hyperuricemic nephropathy through inhibiting inflammation, fibrosis and oxidative stress. Basic & Clinical Pharmacology & Toxicology, 131(6), 474. https://doi.org/10.1111/bcpt.13793

Chicago Style (17th ed.) Citation

Jiang, Xinghao, Qing Wu, Yeboah Kwaku Opoku, Yimeng Zou, Dan Wang, Changhui Hu, and Guiping Ren. "Fibroblast Growth Factor 21 Attenuates the Progression of Hyperuricemic Nephropathy Through Inhibiting Inflammation, Fibrosis and Oxidative Stress." Basic & Clinical Pharmacology & Toxicology 131, no. 6 (2022): 474. https://doi.org/10.1111/bcpt.13793.

MLA (9th ed.) Citation

Jiang, Xinghao, et al. "Fibroblast Growth Factor 21 Attenuates the Progression of Hyperuricemic Nephropathy Through Inhibiting Inflammation, Fibrosis and Oxidative Stress." Basic & Clinical Pharmacology & Toxicology, vol. 131, no. 6, 2022, p. 474, https://doi.org/10.1111/bcpt.13793.